Related Experiment Videos
[Distribution of 4-14C-mofebutazone in the rat]
Zeitschrift Fur Rheumatologie
|March 1, 1986
Summary
Mofebutazone rapidly distributes to elimination organs and is quickly excreted, with nearly 81% eliminated in 24 hours. This rapid excretion prevents drug accumulation in rats, suggesting a low risk of toxicity.
Area of Science:
- Pharmacokinetics
- Drug Metabolism
- Toxicology
Background:
- Mofebutazone and phenylbutazone are nonsteroidal anti-inflammatory drugs (NSAIDs).
- Understanding mofebutazone's distribution and elimination is crucial for assessing its safety profile.
- Comparative pharmacokinetic data between mofebutazone and phenylbutazone is limited.
Purpose of the Study:
- To investigate the distribution and elimination of mofebutazone in rats.
- To compare the pharmacokinetic profile of mofebutazone with phenylbutazone.
- To determine the potential for mofebutazone accumulation in tissues.
Main Methods:
- Administered 4-14C-mofebutazone (200 mg/kg) to 6 rats.
- Measured plasma levels and urinary excretion of radioactivity at 45 min, 6 h, and 24 h.
- Utilized whole-body autoradiography to visualize tissue distribution.
Main Results:
- Mofebutazone primarily distributed to metabolization and elimination organs.
- Moderate radioactivity detected in skin and muscle tissue; none in CNS or bone marrow.
- Nearly 81% of the dose was eliminated within 24 hours, mainly via urine.
- Autoradiograms showed minimal residual activity after 24 hours, except in the colon.
Conclusions:
- Mofebutazone exhibits rapid elimination and a short half-life in rats.
- The drug does not appear to accumulate in tissues, indicating a favorable safety profile.
- These findings suggest a lower risk of toxicity compared to drugs with longer elimination times.